文献速递前列腺癌

丹麦人群中活检分级分组1前列腺癌诊断的结局

Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
PubMed 文献 · Eur Urol Oncol · 2023-10-25

该研究基于丹麦前列腺登记数据库,描述全国所有活检分级分组1(GG 1)前列腺癌男性的结局,重点分析保守随访者。结果显示,初始主动监测者10年内分泌治疗累积发生率为5.3%(95%CI 4.3-6.3%),初始等待观察的局限期GG 1者为21%(95%CI 19-23%);等待观察者15年前列腺癌特异性死亡率为14%(95%CI 11-16%)。作者认为GG 1癌可导致疾病特异性死亡,对所有男性更改命名可能导致治疗不足。

要点

  • 初始主动监测的GG 1男性10年内分泌治疗累积发生率为5.3%(95%CI 4.3-6.3%)。
  • 初始等待观察的局限期GG 1男性10年内分泌治疗累积发生率为21%(95%CI 19-23%)。
  • 等待观察的GG 1男性15年前列腺癌特异性死亡率为14%(95%CI 11-16%)。

核心结论

  • GG 1癌在局限期前列腺癌男性中可导致疾病特异性死亡,对所有男性更改命名可能导致治疗不足。

研究设计与样本

  • 基于丹麦前列腺登记数据库的全国人群观察性研究,纳入丹麦所有诊断为GG 1前列腺癌的男性。

主要发现

  • 初始主动监测的GG 1男性10年内分泌治疗累积发生率为5.3%(95%CI 4.3-6.3%)。
  • 初始等待观察的局限期GG 1男性10年内分泌治疗累积发生率为21%(95%CI 19-23%)。
  • 等待观察的GG 1男性15年前列腺癌特异性死亡率为14%(95%CI 11-16%)。
  • 等待观察且前列腺特异性抗原<10 ng/ml的GG 1男性15年前列腺癌特异性死亡率为10%(95%CI 6.7-14%)。
  • 未接受根治性意向治疗或组织学评估的GG 1男性15年前列腺癌特异性死亡率为16%(95%CI 13-19%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究受观察资料的历史性质限制,期间诊断程序和治疗已发生演变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Debate regarding a nomenclature change for grade group 1 (GG 1) prostate cancer to noncancer has been revived, as this could be a powerful tool in reducing the overtreatment of indolent disease. OBJECTIVE: To describe outcomes for all men diagnosed with GG 1 prostate cancer in the Danish population, with a focus on men followed conservatively. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based observational study using data from the Danish Prostate Registry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured the cumulative incidence of curative treatment, endocrine treatment, and cause-specific mortality. RESULTS AND LIMITATIONS: The cumulative incidence of endocrine therapy at 10 yr was 5.3% (95% confidence interval [CI] 4.3-6.3%) for men with initial active surveillance and 21% (95% CI 19-23%) for men with initial watchful waiting for localized GG 1. In the GG1 cohort, the prostate cancer-specific mortality rate at 15 yr was 14% (95 CI% 11-16%) for men on watchful waiting, 10% (95 CI% 6.7-14%) for men with prostate-specific antigen <10 ng/ml on watchful waiting, and 16% (95 CI% 13-19%) for men who did not receive curative-intent treatment or histological assessment. The study is limited by the historic nature of the observations over a period during which diagnostic procedures and treatments have evolved. CONCLUSIONS: GG 1 cancer can lead to disease-specific mortality in men with localized prostate cancer, and changing the nomenclature for all men may lead to undertreatment. PATIENT SUMMARY: Key opinion leaders have suggested that prostate cancers of Gleason grade group 1 (GG 1) should be renamed as noncancer to reduce overtreatment. The argument is that low-grade cancer does not metastasize. However, our nationwide population-based study showed that death from prostate cancer can occur in some men diagnosed with GG 1 disease. These men should be considered in discussions on changing the name for GG 1 prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Stroomberg HV, Larsen SB, Kjær Nielsen T, et al. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. 2023. PMID: 37884421. doi:10.1016/j.euo.2023.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。